• AstraZeneca Reports Positive Results From Phase III Trial With Datopotamab Deruxtecan

    来源: NASDAQ US Markets / 22 9月 2023 02:59:00   America/New_York

    (RTTNews) - AstraZeneca PLC (AZN.L, AZN) said high-level results from the TROPION-Breast01 Phase III trial with datopotamab deruxtecan showed a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival compared to invest https://www.nasdaq.com/articles/astrazeneca-reports-positive-results-from-phase-iii-trial-with-datopotamab-deruxtecan
分享